Rexahn announced that it has submitted a Phase 2b protocol to the FDA for the study of Serdaxin for the treatment of major depressive disorder (MDD). The planned double blind, randomized, placebo-controlled trial will include change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) as the primary endpoint.

Serdaxin is a dual serotonin and dopamine enhancer being evaluated as a potential treatment for multiple CNS disorders where these neurotransmitters are depleted or implicated in CNS-based illnesses.

For more information call (240) 268-5300 or visit